Avian Influenza

Hee Jin Cheong

doi:10.5124/jkma.2005.48.12.1195

J Korean Med Assoc > Volume 48(12); 2005 > Article

Cheong: Avian Influenza

Continuing Education Column

Journal of the Korean Medical Association

Journal of the Korean Medical Association 2005; 48(12): 1195-1205.

Published online: December 31, 2005

DOI: http://dx.doi.org/10.5124/jkma.2005.48.12.1195

Avian Influenza

Hee Jin Cheong, M.D.

Department of Internal Medicine, Korea University College of Medicine, Gu-Ro Hospital, Korea. heejinmd@korea.ac.kr

Abstract

Influenza is an acute febrile disease caused by influenza virus (type A or B). Influenza virus is the major culprit of viral diseases in the respiratory tract with the highest mortality in the human history and can affect 10~40% of the general population within only 4 weeks when it is epidemic.

In immunocompetent individuals, influenza infection is mostly limited as 'flu' for several days, but in immunocompromised hosts such as elderly individuals and those with chronic diseases it can result in serious complications such as pneumonia and can also aggravate underlying diseases requiring admission and increasing mortality. Despite the wide application of influenza vaccines for the last decades, influenza still remains an important health issue due to the increase of the susceptible individuals and the recent outbreaks of avian flu along with the emergence of new strains.

Avian Influenza

References

1. World Health Organization. WHO interim guidelines on clinical management of humans infected by influenza A(H5N1) 2004;02. 20.

2. Webster RG, Yakhno M, Hinshaw VS, Bean WJ, Murti KG. Intestinal influenza: replication and characterization of influenza viruses in ducks. Virology 1978;84:268-278.

3. Rogers GN, Paulson JC. Receptor determinants of human and aminal influenza virus isolates: differences in receptor specificity of the H3 hemagglutinin based on species of origin. Virology 1983;127:361-373.

4. Rogers GN, Paulson JC, Daniels RS, Skehel JJ, Wilson IA, Wiley DC. Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity. Nature 1983;304:76-78.

5. Salgado CD, Farr BM, Hall KK, Hayden FG. Influenza in the acute hospital setting. Lancet Infect Dis 2002;2:145-155.

6. Bridges CB, Kuehnert MJ, Hall CB. Transmission of influenza: implications for control in health care settings. Clin Infect Dis 2003;37:1094-1101.

7. Hien TT, Liem NT, Dung NT, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004;350:1179-1188.

8. World Health Organization. . WHO inter-country-consultation: influenza A/H5N1 in humans in Asia 2005;05. 6~7. Manila, Philippines.

9. Liem NT, Lim W. World Health Organization International Avian Influenza Investigation Team, Vietnam. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis 2005;11:210-215.

10. Apisarnthanarak A, Kitphati R, Thongphubeth K, et al. Atypical avian influenza (H5N1). Emerg Infect Dis 2004;10:1321-1324.

11. de Jong MD, Cam BV, Qui PT, et al. Fatal Avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 2005;352:686-691.

12. Beigel JH, Farrar J, Han AM, Hayden FG, Hyer R, Yuen KY, et al. Writing Committee of the World Health Organization (WHO) Consultation on Human Influenza A/H5. Avian influenza A (H5N1) infection in humans. N Engl J Med 2005;353:1374-1385.

13. Chotpitayasunondh T, Ungchusak K, Hanshaoworakul W, et al. Human disease from influenza A (H5N1), Thailand, 2004. Emerg Infect Dis 2005;11:201-209.

14. Hien TT, Liem NT, Dung NT, et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004;350:1179-1188.

15. Kaiser L, Briones MS, Hayden FG. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol 1999;14:191-197.

16. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, Webster RG. The neuraminidase inhibitor GS4104 (oseltamivir phosphate) is efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) influenza viruses. Antiviral Res 2000;48:101-115.

17. Gubareva LV, McCullers JA, Bethell RC, Webster RG. Characterization of influenza A /HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 1998;178:1592-1596.

18. Leneva IA, Goloubeva O, Fenton RJ, Tisdale M, Webster RG. Efficacy of zanamivir against avian influenza A viruses that possess genes encoding H5N1 internal proteins and are pathogenic in mammals. Antimicrob Agents Chemother 2001;45:1216-1224.

19. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. J Infect Dis 2005;192:665-672.

Avian Influenza

Abstract

References

Figure 1

Table 1

Table 2